^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Pathlight™ MRD test

    Company:
    SAGA Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    21d
    SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026 (SAGA Diagnostics Press Release)
    "SAGA Diagnostics...today announced that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29 to June 2 in Chicago."
    Clinical data
    |
    Pathlight™ MRD test
    2ms
    SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026 (SAGA Diagnostics Press Release)
    "SAGA Diagnostics...today announced that the company and its collaborators will present data from two abstracts at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 in San Diego, California. These abstracts showcase the ultrasensitive structural variant (SV)-based detection of circulating tumor DNA (ctDNA) in metastatic breast cancer (mBC) and high-grade serous ovarian cancer (HGSOC)."
    Clinical data
    |
    Pathlight™ MRD test
    5ms
    SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer (SAGA Diagnostics Press Release)
    "SAGA Diagnostics...today announced the launch of its ultrasensitive Pathlight MRD diagnostic test for patients with colorectal cancer (CRC). This expands the clinical application of Pathlight following its successful commercial launch in early-stage breast cancer last year."
    Launch
    |
    Pathlight™ MRD test